Next Phase Newsletter

An evergreen fund that was established in 2013 and is based in Taiwan is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses in the life science space. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

The fund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

The fund is looking for competent, experienced, and reliable management teams when considering investment. Prior to deciding on allocations, the fund’s management team typically spends months interacting with candidate companies to determine their track record, quality of scientific research, technical expertise, and flexibility and reliability in working with investors. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family of private equity funds, which has two US-based offices in, and one operation in Beijing, China is currently looking to make investments in all major areas of the healthcare industry. The firm typically provides equity and equity-related capital to small and emerging healthcare companies at late-clinical stage and commercial stage. The investment size will vary, depending on the opportunity. The firm will consider investment opportunities across the globe with a focus in the US and Asia.

The firm is currently looking for new opportunities in the Therapeutics. Diagnostics, Medical device, Biotech service, Healthcare IT and other healthcare companies. For therapeutics, the firm will invest in both small molecules and biologics, and it typically looks for emerging biopharmaceutical companies with assets later than Phase II. In the medtech sector, the firm will consider all classes of medical devices. The firm generally invests in commercial products and development stage companies that have passed key milestones. Historically, the firm was active in a molecular diagnostics laboratory, medical device companies, healthcare IT companies and biopharmaceutical companies.

The firm focuses on privately held companies that have already established operations or have completed a substantial portion of their development process for new products, technologies and services. The firm looks to take a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A single family office and advisory firm based in the Western United States is looking to make allocations in the life science space. Typical investments are north of $5 million although due to the firm capital structure they can be flexible. The firm is currently seeking new investment opportunities in the US and China.

In life sciences the firm is a generalist in terms of technology sectors including biotech therapeutics, diagnostics and medical devices. That being said, the firm has a special interest in regenerative medicine. The firm prefers to work with pre-IPO life science companies and was recently involved in a round for a company developing orthobiologic products.

The firm is looking for experienced management teams and generally requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large tech company is actively seeking investments in the life science space. The firm manages two venture funds worth a total of $1.1B; focus on early-stage companies; target companies of all sizes respectively.  The firm is actively seeking new investment opportunities and is open to review opportunities from around the globe.

In the Life Sciences, the firm seeks to invest in Mobile healthcare IT, bio authentication, fitness and wellness measurement algorithm (i.e. Fitbit and Basis type of companies), calorie measurement, heart measurement, glucose measurement, and medical imaging equipment technology (i.e. Ultrasound, MRI, CAT scan, and image enhancement and distribution tech). The firm is open to reviewing companies of all stages.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A European Evergreen Investment Firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients. The firm is actively screening new investment opportunities and is open to reviewing opportunities from around the globe.

The firm seeks to invest in early-late stage biotech therapeutics, diagnostics, medical devices, and healthcare IT. Currently, the firm is highly interested in Gene and Cell therapies and patient stratification. Technologies/products that target orphan diseases or small patient populations are also of interest. The firm only selects truly revolutionary technologies and has no interest in incremental improvements to efficacy/safety.

The firm seeks to be a long term investor and does not look to exit or IPO their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

The firm is looking from companies with experienced management teams and will seek a board seat on a case by case basis when it is appropriate to do so. The firm is generally more comfortable with co-investing in early stage opportunities although they are not completely opposed to leading a round if the right opportunity were to present itself.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm is also willing to consider medical devices targeting these indication.

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com